191 related articles for article (PubMed ID: 21439039)
21. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract][Full Text] [Related]
22. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
Schou JV; Rossi S; Jensen BV; Nielsen DL; Pfeiffer P; Høgdall E; Yilmaz M; Tejpar S; Delorenzi M; Kruhøffer M; Johansen JS
PLoS One; 2014; 9(6):e99886. PubMed ID: 24940606
[TBL] [Abstract][Full Text] [Related]
23. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
Asai H; Shinozaki E; Nozaki A; Watanabe T; Suenaga M; Matuzaka S; Chin K; Mizunuma N; Yasukawa M; Hatake K
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1285-91. PubMed ID: 21829065
[TBL] [Abstract][Full Text] [Related]
25. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
26. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
27. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
30. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.
Saridaki Z; Tzardi M; Papadaki C; Sfakianaki M; Pega F; Kalikaki A; Tsakalaki E; Trypaki M; Messaritakis I; Stathopoulos E; Mavroudis D; Georgoulias V; Souglakos J
PLoS One; 2011 Jan; 6(1):e15980. PubMed ID: 21283802
[TBL] [Abstract][Full Text] [Related]
31. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
32. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
[TBL] [Abstract][Full Text] [Related]
33. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Giessen C; Moosmann N; Heinemann V
Br J Cancer; 2011 Jul; 105(2):206-11. PubMed ID: 21750558
[TBL] [Abstract][Full Text] [Related]
34. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Prenen H; De Schutter J; Jacobs B; De Roock W; Biesmans B; Claes B; Lambrechts D; Van Cutsem E; Tejpar S
Clin Cancer Res; 2009 May; 15(9):3184-8. PubMed ID: 19366826
[TBL] [Abstract][Full Text] [Related]
36. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
37. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
[TBL] [Abstract][Full Text] [Related]
39. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
Khan SA; Zeng Z; Shia J; Paty PB
Pathol Oncol Res; 2017 Jul; 23(3):673-677. PubMed ID: 28025786
[TBL] [Abstract][Full Text] [Related]
40. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Iwamoto S; Hazama S; Kato T; Miyake Y; Fukunaga M; Matsuda C; Bando H; Sakamoto J; Oba K; Mishima H
Anticancer Res; 2014 Apr; 34(4):1967-73. PubMed ID: 24692733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
